Clinical trial shows improved gut microbiota and peptide levels in IBS-D patients following moxibustion, suggesting new therapeutic avenues.
Key Points
Yin Yang regulating moxibustion reduced symptom severity scores in patients with diarrhea-predominant irritable bowel syndrome.
After treatment, patients receiving moxibustion exhibited a significant improvement in gut microbiota structure compared to those receiving only medication.
The treatment group had lower brain gut peptide levels after therapy compared to the control group, indicating effective physiological changes.
No serious adverse reactions were reported during the treatment, confirming the safety of moxibustion as a complementary therapy.